Navigation Links
Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
Date:12/8/2009

NEW ORLEANS, Dec. 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today an abstract to be published online at the journal Blood website by M. Hacker, et al. demonstrating significant reduction in cardiac cell toxicity with pixantrone compared to currently marketed anthracyclines. The authors conclude that the reduction is due to pixantrone's inability to generate toxic drug iron complexes and reduced propensity to generate oxygen free radicals. Pixantrone was specifically designed to have a higher affinity and avidity for the topisomerase II enzyme, which is the common target for this class of anti-cancer agents, while reducing oxygen-free radicals and preventing the formation of toxic drug metal complexes, which are the primary culprit that leads to dose-related irreversible heart damage associated with standard anthracyclines.

"This study adds to the growing scientific evidence which is central to the mechanistic basis for the relatively low incidence of cardiac events observed in our pixantrone clinical trials compared to the expected incidence of events had other anthracyclines been used. The ability to reintroduce an effective anthracycline like agent to patients who are no longer eligible to receive further standard anthracycline therapy due to potential irreversible heart damage addresses a major and growing unmet medical need," Jack Singer, M.D., Chief Medical Officer of Cell Therapeutics, Inc.

About the Study

To validate the proposed mechanisms underlying the observed differences in cardiotoxicity, researchers used established spectrophotometric techniques to quantify iron and drug interactions that are thought to be mechanistic for chronic doxorubicin cardiotoxicity. When adding increasing amounts of iron to drug solutions, they observed that doxorubicin and mitoxantrone underwent changes in visible range absorbance patterns, which is charact
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BD Ranked in the Top 100 Greenest Big Companies by Newsweek; Named Again to Dow Jones Sustainability World and North America Indexes
2. US Oncology, Inc. to Exhibit iKnowMed(TM) at the 2009 ASCO EHR Symposium: Harnessing the EHR: From Incentives to Sustainability
3. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
4. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
5. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
6. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
7. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
8. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
9. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
10. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
11. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/14/2014)... Jan. 14, 2014 HeartWare International, Inc . ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... it expects revenues for the fourth quarter of 2013 ... revenues to approximately $208 million. "Our full-year ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led by ... a premier and affordable laser tattoo removal experience with the ... focus is in providing high quality cosmetic services with cutting edge ... " Southern California has seen a dramatic ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... Connecticut waterways may be safer from biomedical waste, thanks ... program. CEDF, with loan-program partners, Connecticut ,s Department of Economic and Community ... loan to a West Haven company that stems improper disposal of ... , West ...
... 14 Hospira, Inc. (NYSE: ... medication delivery company, will expand its commitment to non-DEHP ... of non-DEHP intravenous (I.V.) administration sets. This effort reflects ... and reduced impact on the environment, and coincides with ...
Cached Medicine Technology:West Haven Firm Expands Biomedical Disposal Program with Community Economic Development Fund 2Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP 2Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP 3Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP 4
(Date:4/22/2014)... lung cancer are 70 years of age or older, ... not well represented in clinical trials. Therefore, the paucity ... evidence based clinical recommendations. , In 2010, the EORTC ... Group along with the International Society for Geriatric Oncology ... elderly patients with non-small cell lung cancer (NSCLC), and ...
(Date:4/22/2014)... to trauma, illness, alcohol or other drug abuse, these ... cells that can go awry and activate conditions such ... autism. , Until now, it has been unclear how ... developing brain. Past studies have shown that when an ... or she experiences some trauma or illness, her baby ...
(Date:4/22/2014)... (April 22, 2014) Cedars-Sinai stroke intervention researchers have ... and Stroke, part of the National Institutes of Health, ... multicenter Phase II clinical trial of an experimental drug ... used in combination with recombinant tissue plasminogen activator, or ... ischemic strokes shortly after onset. In laboratory rodent studies, ...
(Date:4/22/2014)... Based on results of a clinical trial ... Food and Drug Administration (FDA) approved a molecularly ... cancer that has progressed after standard chemotherapy has ... review was announced by the manufacturer, Lilly Oncology, ... name ramucirumab, it will be sold under the ...
(Date:4/22/2014)... of the University of Calgary,s Hotchkiss Brain Institute (HBI) ... cells as a means to restore connections after injury. ... key molecule that directly regulates nerve cell growth in ... the prestigious journal Nature Communications , with lead ... "We made the surprising discovery that a protein called ...
Breaking Medicine News(10 mins):Health News:EORTC and SIOG update expert opinion on management of elderly patients with NSCLC 2Health News:Life stressors trigger neurological disorders, researchers find 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 3Health News:FDA approves first targeted drug for advanced stomach cancer 2Health News:Scientists discover a new way to enhance nerve growth following injury 2
... BELLEVUE, Wash. and WASHINGTON, Oct. 4 Revolution,Health ... fastest growing health,properties, and drugstore.com (Nasdaq: DSCM ... and pharmacy products, today announced a major,agreement whereby ... the Revolution Health Network and manage advertising sales ...
... and Research,s (A*STAR) Institute of Molecular and Cell ... provide a more detailed understanding of how the ... albicans transforms into a serious and often life-threatening ... serious and potentially life-threatening infections in the mouth, ...
... FAIRFAX, Va., Oct. 4 SRA International, Inc.,(NYSE: ... and strategic consulting,services and solutions to federal government ... an enterprise-wide infrastructure,architecture for the Department of Justice ... Support Services-3 contract, has an,estimated value of $59 ...
... ,Tour to Insure, will Highlight Need to Reduce,Costs, Expand ... G.,Rendell will continue his campaign to reduce the costs ... with the passage of the,remainder of his "Prescription for ... bus tour. The five-day, nine-stop "Tour to Insure",will include ...
... operational,clinical and technological innovator in emergency medical services, ... ground, this time in the,way it hires the ... and around,Charlotte, N.C. While the nation,s emergency ... already trained in an academic setting,Medic is hiring ...
... Drive for Decision, CHARLESTON, S.C., Oct. 4 ... to introduce a proactive self-funding process to,secure the ... for the domestic shrimping industry. Beginning in January ... combination of federal government,assistance, voluntary industry contributions, foundation ...
Cached Medicine News:Health News:drugstore.com and Revolution Health Group Announce Breakthrough Deal 2Health News:drugstore.com and Revolution Health Group Announce Breakthrough Deal 3Health News:How Candida albicans transforms from its normally benign form into life-threatening form 2Health News:Department of Justice Awards $59M Task Order to SRA 2Health News:Governor Rendell to Fight to 'Cover All Pennsylvanians' During Statewide Bus Tour 2Health News:Mecklenburg EMS Agency Launches Innovative Program to Pay Future EMT's While They Train 2Health News:Wild American Shrimp Board Agrees To Implement New Self-Funding Measures 2
Full Handle Laseredge Stab Blade Knife, 30 blade. Blade tip dimension: 10.5 mm x 1.9 mm x 3.4 mm....
19 Gauge. Reusable. Block of 4 each....
Set consist of two 27 gauge, stainless steel probes with blunt tips. Probes are 11.5 cm (4.5 inches) long with 30.5 cm (12 inches) of flexible tubing (O.D. - 0.60 mm, I.D. - 0.30 mm) attached onto th...
19 gauge x 8 mm with 15 cm high pressure extension tube preattached to a 10C ring control syringe. 3 per box....
Medicine Products: